GlobeNewswire

Cloudian and Storage Made Easy Launch GDPR-Ready Enterprise File Sync-and-Share Solution

Dela

Ensures compliance by controlling user data location and access, while monitoring for use of regulated personal data

LONDON and SAN MATEO, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Cloudian® and Storage Made Easy® (SME) have launched a General Data Protection Regulation (GDPR)-ready, enterprise-wide file sync-and-share solution, designed to eliminate the compliance exposure of external cloud-based file sharing services where personal data or company confidential information may reside outside the direct control of the IT organization.

The combined solution includes on-premises storage and GDPR-ready collaboration software with access controls and content indexing to continuously monitor for the use of regulated personal data, recognising more than 60 data types including credit card, passport and social security numbers.

Unlike most cloud-based file sharing services, the Cloudian/SME solution lets IT managers control their data's physical location and manage access permissions via existing company authentication frameworks such as Active Directory and LDAP. The solution also provides secure file sharing controls such as password-protected links, configurable download limits, and expiration dates after which links will be disabled automatically. All data accesses are logged, maintaining an audit trail for compliance.   

"With GDPR now in effect, organizations must implement tight controls over data location and usage -- particularly when personal data is at stake -- requirements that most cloud-based services do not meet," said Michael Tso, CEO of Cloudian. "The Cloudian/SME solution gives IT managers peace-of-mind, with end-to-end control of data location and access, and a continuous view of where files are stored, how they are shared, and where personal data is employed."

Compatible with Windows, Mac, Linux, iOS and Android platforms, the solution includes configurable synchronization options that let users control where data is replicated, and integration with Microsoft Office and email applications that allow users to securely access and share files.

"Users are going to share information, but that does not mean that IT managers need to lose control. The challenge is to provide easy-to-use file sharing that boosts productivity while ensuring that sensitive information remains secure," said Jim Liddle, CEO of Storage Made Easy. "Cloudian and SME together provide the best of both worlds, combining the simplicity of a cloud-like solution, the security of on-premises storage, and the comprehensive compliance enforcement afforded by our GDPR-ready feature set."

Multiple privacy regulations mandate strict controls on data handling, including the EU General Data Protection Regulation and the California Consumer Privacy Act of 2018. These require that companies collecting personal data - which includes a wide range of information such as names, identification numbers, location data or online identifiers - both protect the data and delete it if requested. Compliance requires tight controls on how such information is stored and used.

"Our customers needed a turnkey solution to simplify compliance, and we responded with CloudDrive, a Cloudian and Storage Made Easy-based solution that provides GDPR-aligned file sync-and-share service for the enterprise," said Julian Box, CEO at Calligo. "With Cloudian storage and SME software, our customers get easy-to-use file sharing and powerful data management tools that keep IT in control, making compliance one less thing to worry about."

About Store Made Easy
Storage Made Easy provides a multi-cloud data management and data protection product called the Enterprise File Fabric(TM) that unifies on-premises and on-cloud company storage assets, in addition to standalone products that bridge desktop and cloud, such as operating system-native cloud drives and cloud explorer applications. The company is backed by one of the largest alternative asset managers in addition to entrepreneurs in the London market insurance industry, who have previously successfully sold their company to a listed peer.

Storage Made Easy is the trading name of Vehera LTD. Follow us on Twitter @SMEStorage and visit us at www.StorageMadeEasy.com to learn more.

About Cloudian
Cloudian turns information into insight with an infinitely scalable platform that consolidates, manages and protects enterprise data. Cloudian data management solutions bring cloud technology and economics to the data centre with uncompromising data durability, intuitive management tools, and the industry's most compatible S3 API. Cloudian and its ecosystem partners help Global 1000 customers simplify unstructured data management today, while preparing for the data demands of AI and machine learning tomorrow.

Join us on LinkedIn, follow us on Twitter (@CloudianStorage) and Facebook, or visit us at www.cloudian.com.

Media Contacts

Emily Gallagher
Touchdown PR 
Cloudian@touchdownpr.com
+44 (0)1252 717040

Alex Mercurio
10Fold Communications 
cloudian@10fold.com 
949-940-5656




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cloudian via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum